Trying to determine if a patient has recurrent disease vs. adverse radiation effect after radiation therapy for brain mets? 18F-fluciclovine PET criteria based on full histopath in this prospective phase 2 study! authors.elsevier.com/sd/article/S03…
2
9
23
975
Rupesh Kotecha retweeted
At #NRG2025 in Washington, DC, we asked @Rrkotecha to discuss the NRG-CC014 (PREEMPT) & NRG-BN014 clinical trials. Dr. Kotecha is the radiation oncology chair for both studies. Watch both interviews on our YouTube channel: youtube.com/@NRGOnc
0
2
1
604
Rupesh Kotecha retweeted
Does the addition of radiofrequency ablation/vertebral augmentation to radiotherapy improve pain outcomes for painful spine mets?
NO according to this Phase IIR academic.oup.com/neuro-oncology…
NO according to this Phase IIR academic.oup.com/neuro-oncology…
2
8
29
1,551
Rupesh Kotecha retweeted
Learn from #MiamiCancerInstitute experts @MikeChuongMD @Rrkotecha @Sarbaji85064063 + Dr. Yuliya Linhares as they present groundbreaking Phase II clinical trials and oncology innovations. FREE Registration: bapth.lt/BioMedSymp 🍍
Join us for the Baptist Health Biomedical Research Symposium where experts will share insights on:
✅ Advancing translational research & clinical trials
✅ Groundbreaking therapies shaping patient care in South Florida
✅ Emerging technologies in #oncology, #cardiology, #neuThis symposium brings together physicians, APPs, nurses, pharmacists, residents, students & research staff to explore the future of care.
cmeonline.baptisthealth.net/biomedical-res…
0
4
8
1,329
Rupesh Kotecha retweeted
May is #BrainCancerAwarenessMonth! We asked @Rrkotecha, NRG-BN013 Principal Investigator, to discuss this Phase III study of single fraction stereotactic radiosurgery (SRS) versus fractionated SRS (fSRS) for intact brain metastases youtube.com/watch?v=s-MWC4…
0
1
6
803
Rupesh Kotecha retweeted
Pertinent ongoing trial NRG BN014 Proton CSI vs involved field RT for Breast CA or NSCLC LMD
(RADIATE-LM) PI @JYangMDPhD @wgbreen @JHGLab @Rrkotecha @BrainTumorDoc
(RADIATE-LM) PI @JYangMDPhD @wgbreen @JHGLab @Rrkotecha @BrainTumorDoc
0
1
3
427
Rupesh Kotecha retweeted
Thanks to @QuadShotNews for highlighting our analysis
-138 pts w/ abd mets mostly LN, adrenal gland, liver
-Most lung/GI primaries
-SMART on 035.T MRL, med 50 Gy/5 fx
-Online ART 77% of fx
-GTV 95%=98.1 Gy BED10🔥
-2yr LC 84%
-Acute/late gr3 tox 0%/2.2%
redjournal.org/article/S0360-…
-138 pts w/ abd mets mostly LN, adrenal gland, liver
-Most lung/GI primaries
-SMART on 035.T MRL, med 50 Gy/5 fx
-Online ART 77% of fx
-GTV 95%=98.1 Gy BED10🔥
-2yr LC 84%
-Acute/late gr3 tox 0%/2.2%
redjournal.org/article/S0360-…
2
8
22
2,132
Rupesh Kotecha retweeted
🚀Ph2 SMART ONE trial in press
🔹1-fx SBRT on 0.35T MR-Linac
🔹2/3 targets abd/pelvis, 1/3 lung
🔹🔥🔥 plans!! Median GTV mean dose: adrenal 32.3 Gy, LN 31.7 Gy, liver 45.4 Gy, lung 42.8 Gy
🔹Median time 53 min, ART routine
🔹1-yr LC 96.2%, 1-yr OS 86.3%
redjournal.org/article/S0360-…
🔹1-fx SBRT on 0.35T MR-Linac
🔹2/3 targets abd/pelvis, 1/3 lung
🔹🔥🔥 plans!! Median GTV mean dose: adrenal 32.3 Gy, LN 31.7 Gy, liver 45.4 Gy, lung 42.8 Gy
🔹Median time 53 min, ART routine
🔹1-yr LC 96.2%, 1-yr OS 86.3%
redjournal.org/article/S0360-…
3
17
58
10,678
📢Very proud of our recent publications from @MiamiCancerInst ...results of SMART ONE, proton RICE categorization, and SBRT for infra-diaphragmatic oligomets with MRgRT...something for everyone, check it out now online at @IJROBP! @MikeChuongMD
1
9
28
1,504
Rupesh Kotecha retweeted
Can’t wait to see wonderful colleagues and hear exciting talks from world-renowned experts at the @ClevelandClinic 17th Annual International Symposium on SBRT & SRS. Don’t miss this! There is still time to register: ccfcme.org/SBRT
2
7
28
1,751
Rupesh Kotecha retweeted
I was supposed to present a ph3 trial concept for medically inoperable but technically resectable stage I-II pancreatic cancer today to NCI pancreas task force. But that was cancelled while I was on the ✈️ to San Fran… 🤨
What % of upfront resectable PDAC have surgery?
What % of upfront resectable PDAC have surgery?
3
3
10
1,360
Rupesh Kotecha retweeted
Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer. #lcsm | @Rrkotecha @MiamiCancerInst @BHCancerCare @BaptistHealthSF
targetedonc.com/view/systemic-…
targetedonc.com/view/systemic-…
0
5
7
642
Rupesh Kotecha retweeted
Rupesh Kotecha, MD, (@Rrkotecha) discussed a machine learning tool designed to predict local failure after stereotactic radiosurgery for brain metastases. #ASTRO24 | @MiamiCancerInst @BHCancerCare @BaptistHealthSF
targetedonc.com/view/machine-l…
targetedonc.com/view/machine-l…
0
6
9
856
Rupesh Kotecha retweeted
The NRG-BN013 phase III clinical trial was recently activated as a part of the NRG Oncology brain tumor portfolio. NRG-BN013 will compare two schedules of stereotactic radiosurgery (SRS) for patients with intact brain metastases. @Rrkotecha Read more: ow.ly/7Paq50Tmfma
0
8
11
1,527
Excited to be open to accrual! Lucky number NRG BN013 - a phase 3 randomized trial of SRS vs. FSRS for intact brain mets @NRGonc @JYangMDPhD @MartinTomMD @BrainTumorDoc @DrVogelbaum @MeiPolley
3
20
65
4,076
Rupesh Kotecha retweeted
Congratulations to Dr. Rupesh Kotecha and our #RadOnc team at @MiamiCancerInst for the newly published study highlighting outcomes for patients with large brain metastasis treated with SRS, FSRS, and surgery in the Journal of Neuro-Oncology @JNeurooncol ➡️ bapth.lt/3KxWwS7
@Rrkotecha @BrainTumorDoc @MWMCD @OdiaYazmin @BaptistHealthSF
@Rrkotecha @BrainTumorDoc @MWMCD @OdiaYazmin @BaptistHealthSF
0
4
8
685
Rupesh Kotecha retweeted
How do we manage IDHm LGG post-INDIGO?
· Multi-disciplinary decision-making mandatory
· Vorasidenib active agent reasonable for intermediate risk patients
· OS Impact Vorasidenib unknown (+ = or -) ascopubs.org/doi/10.1200/JC…
· Multi-disciplinary decision-making mandatory
· Vorasidenib active agent reasonable for intermediate risk patients
· OS Impact Vorasidenib unknown (+ = or -) ascopubs.org/doi/10.1200/JC…
3
16
40
13,188
Rupesh Kotecha retweeted
Work hard play hard! 😎💪
The @MiamiCancerInst team and @DrVogelbaum enjoyed a productive day of meetings and then the #NRG2023 reception.
I’m fortunate to work with this brilliant group everyday! 🤩🤩
The @MiamiCancerInst team and @DrVogelbaum enjoyed a productive day of meetings and then the #NRG2023 reception.
I’m fortunate to work with this brilliant group everyday! 🤩🤩
4
3
23
2,057
Rupesh Kotecha retweeted
@MrBeast #pancreaticcancer is one of the deadliest cancers. We need funding for practice changing #clinicaltrials. Our ablative #MRIdian therapy data show incredible survival improvements even for very advanced tumors! Help us change the face of this disease! 🙏🙏
broadcastmed.com/cancer/1106/ne…
broadcastmed.com/cancer/1106/ne…
1
4
14
33,798
Rupesh Kotecha retweeted
Our #MiamiCancerInstitute experts shared the latest #cancerresearch at @ASCO 2023 this year. Presentations focused on brain #metastases, #bladdercancer, #lungcancer, #glioblastoma, and more. Check out some great footage of our experts in action! #ASCO23 #MedTwitter
0
5
22
3,959